• Data, including overall survival, from ARC-10, a randomized study evaluating domvanalimab plus zimberelimab in front-line, PD-L1-high, locally advanced or metastatic non-small cell lung cancer (NSCLC), will be presented in a late-breaking poster presentation
  • An oral presentation will highlight data from an Investigator Sponsored Trial for domvanalimab and zimberelimab in anti-PD-1 refractory hepatocellular carcinoma, demonstrating further proof of concept for the Fc-silent anti-TIGIT antibody domvanalimab
  • Arcus will discuss the ARC-10 results in more detail on its earnings call at 2:00 PM PT / 5:00 PM ET on Wednesday, November 6, 2024

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced four accepted abstracts at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, taking place in Houston, Texas, November 6 – 10, 2024.

A late-breaking poster presented by Melissa L. Johnson, M.D., director, lung cancer research, Sarah Cannon Research Institute, will highlight safety and efficacy data, including objective response rate, progression-free survival and overall survival from ARC-10. This study is a randomized, open-label, three-arm study evaluating domvanalimab, an Fc-silent anti-TIGIT monoclonal antibody, plus zimberelimab, an anti-PD-1 monoclonal antibody, versus zimberelimab or chemotherapy, in patients with front-line locally advanced or metastatic squamous or non-squamous NSCLC with a PD-L1 tumor proportion score of ≥50% without the presence of any tumor genomic aberration or driver mutation for which a targeted therapy is approved. ARC-10 was initially initiated and conducted as a randomized Phase 3 trial; the protocol was subsequently amended to evaluate domvanalimab plus zimberelimab versus pembrolizumab. The study was conducted in partnership with Gilead Sciences.

“The ARC-10 late-breaking poster will include the first overall survival results to be reported for the combination of domvanalimab and zimberelimab, and further build on the evidence that an Fc-silent anti-TIGIT antibody may provide differentiated efficacy and safety relative to the Fc-enabled anti-TIGIT antibodies,” said Terry Rosen, Ph.D., chief executive officer of Arcus.

Four Accepted Abstracts Will Be Presented

Study

Title

Abstract Number

Session Type

Session Date & Time

Domvanalimab (Fc-silent anti-TIGIT monoclonal antibody) plus Zimberelimab (anti-PD-1 antibody)

ARC-10

Randomized Study of Domvanalimab Combined with Zimberelimab in Front-Line, PD-L1 High, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC): Results from ARC-10

1461

Late-Breaking Poster Session

11/8/2024, 9:00 AM – 7:00 PM CST

Investigator Sponsored Trial

Dual TIGIT and PD-1 Blockade With Domvanalimab Plus Zimberelimab in Hepatocellular Carcinoma Refractory to Anti-PD-1 Therapies

603

Oral Presentation, Concurrent Session 107c: Timing and Combination of Systemic Therapies in Solid Cancers

11/8/2024, 3:50 PM – 5:25 PM CST

 

TIGIT Blockade by Monoclonal Antibodies Promotes T Cell Activation and Anti-Tumor Activity That is Not Dependent on a Functionalized Fc Domain

507

Poster Session

11/8/2024, 9:00 AM – 7:00 PM CST

Etrumadenant (A2a/A2b receptor antagonist)

ARC-9

The Adenosine Receptor Antagonist Etrumadenant Reduces Tumor Adenosine-Regulated NR4A Gene Expression and Increases mCRC Inflammation in Patients from the ARC-9 Trial

52

Poster Session

11/9/2024, 9:00 AM – 8:30 PM CST

About Arcus Biosciences

Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of multiple investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, HIF-2a, CD73, dual A2a/A2b receptor, CD39, and AXL. For more information about Arcus Biosciences’ clinical and preclinical programs, please visit www.arcusbio.com.

Domvanalimab, zimberelimab and etrumadenant are investigational molecules. Arcus and Gilead have not received approval from any regulatory authority for any commercial use globally, and their safety and efficacy have not been established.

Forward Looking Statements

This press release contains forward-looking statements. All statements regarding events or results to occur in the future contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, the statements in Dr. Rosen’s quote and statements regarding: the mechanisms of action for any of our investigational products; and current or future combinations involving our investigational products, including the potential benefit or effect of any such combinations. All forward-looking statements involve known and unknown risks and uncertainties and other important factors that may cause Arcus’s actual results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, risks associated with: interim data not being replicated in future studies evaluating the same investigational molecules or regimen; the unexpected emergence of adverse events or other undesirable side effects in Arcus’s investigational products, including domvanalimab and zimberelimab; risks associated with the manufacturing or supplying product for such clinical trials; Arcus’s dependence on the collaboration with Gilead for the successful development and commercialization of its optioned molecules; and the inherent uncertainty associated with pharmaceutical product development and clinical trials. Risks and uncertainties facing Arcus are described more fully in the “Risk Factors” section of Arcus’s most recent periodic report filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this press release. Arcus disclaims any obligation or undertaking to update, supplement or revise any forward-looking statements contained in this press release except to the extent required by law.

The Arcus name and logo are trademarks of Arcus Biosciences, Inc. All other trademarks belong to their respective owners.

Investor Inquiries: Pia Eaves               VP of Investor Relations & Strategy (617) 459-2006 peaves@arcusbio.com

Media Inquiries: Holli Kolkey VP of Corporate Affairs (650) 922-1269 hkolkey@arcusbio.com

Arcus Biosciences (NYSE:RCUS)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024 Arcus Biosciences 차트를 더 보려면 여기를 클릭.
Arcus Biosciences (NYSE:RCUS)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024 Arcus Biosciences 차트를 더 보려면 여기를 클릭.